Pancreatic cancer physical examination


 * Associate Editor-In-Chief:

Overview
During physical examination, a clinician may find characteristics of pancreatic cancer in a patient. These include: pain,. weight loss, or jaundice.

Physical Examination
Most patients with pancreatic cancer experience pain, weight loss, or jaundice.

Pain is present in 80 to 85 percent of patients with locally advanced or advanced metastic disease. The pain is usually felt in the upper abdomen as a dull ache that radiates straight through to the back. It may be intermittent and made worse by eating. Weight loss can be profound; it can be associated with anorexia, early satiety, diarrhea, or steatorrhea. Jaundice is often accompanied by pruritus and dark urine. Painful jaundice is present in approximately one-half of patients with locally unresectable disease, while painless jaundice is present in approximately one-half of patients with a potentially resectable and curable lesion.

The initial presentation varies according to location of the cancer. Malignancies in the pancreatic body or tail usually present with pain and weight loss, while those in the head of the gland typically present with steatorrhea, weight loss, and jaundice. The recent onset of atypical diabetes mellitus, a history of recent but unexplained thrombophlebitis (Trousseau's sign), or a previous attack of pancreatitis are sometimes noted.

Courvoisier sign defines the presence of jaundice and a painlessly distended gallbladder as strongly indicative of pancreatic cancer, and may be used to distinguish pancreatic cancer from gallstones.

Tiredness, irritability and difficulty eating due to pain also exist. Pancreatic cancer is usually discovered during the course of the evaluation of aforementioned symptoms.

Liver function tests can show a combination of results indicative of bile duct obstruction (raised conjugated bilirubin, γ-glutamyl transpeptidase and alkaline phosphatase levels). CA19-9 (carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks sensitivity and specificity. When a cutoff above 37 U/mL is used, this marker has a sensitivity of 77% and specificity of 87% in discerning benign from malignant disease. CA 19-9 might be normal early in the course, and could be elevated due to benign causes of biliary obstruction.

Imaging studies, such as computed tomography (CT scan) can be used to identify the location of the cancer. Endoscopic ultrasound (EUS) is another procedure that can help visualize the location and can serve to guide a percutaneous needle biopsy, which is necessary to establish a definitive diagnosis.

Recent research indicates that in pancreatic cancer malignancies, the tumor contains markedly higher levels of certain microRNAs (miRNA) than does the patient's benign pancreatic tissue or that found in other healthy pancreases. This paves the way for two possibilities:


 * a more early but likely expensive genetic and biochemical molecular screening test profile, which would be an innovation in this cancer;
 * also possible new, creative and more effective therapies based on the various microRNA levels. This opens an exciting new front in confronting a very deadly disease.

As a summary; tests that examine the pancreas are used to detect (find), diagnose, and stage pancreatic cancer as follow:
 * Physical exam and history
 * Tumor markers
 * Chest x-ray
 * CT scan (CAT scan)
 * MRI (magnetic resonance imaging)
 * PET scan (positron emission tomography scan)
 * Endoscopic ultrasound (EUS): This procedure is also called endosonography.
 * Laparoscopy
 * Endoscopic retrograde cholangiopancreatography (ERCP)
 * Percutaneous transhepatic cholangiography (PTC): This test is done only if ERCP cannot be done.
 * Biopsy